Objective We studied the longitudinal association between adiponectin and cardiac structure and function 10 years later stratified by hypertension status.
Background
Adiponectin is a protein mainly produced by adipose tissue, although cardiac myocytes also produce adiponectin [1, 2] . Adiponectin concentrations are correlated inversely with BMI [1] . Adiponectin benefits the heart in several ways: it directly increases coronary blood flow, increases vascular endothelial growth factor production, leading to increased coronary angiogenesis, and protects against reactive oxygen species, angiotensin II-induced fibrosis, and tumor necrosis factor-α-induced apoptosis of myocytes [3] [4] [5] [6] [7] [8] . Some earlier studies have also shown that individuals with low adiponectin have an increased risk of hypertension, although this finding is not consistent across all studies [9] [10] [11] . However, some earlier studies showed that higher adiponectin was associated with higher coronary artery calcium and serum markers of oxidative stress, as well as more heart failure and mortality in patients with ischemic heart disease [12, 13] .
Several earlier studies showed that higher adiponectin was cross-sectionally associated with lower left ventricular (LV) ejection fraction and LV mass [14] [15] [16] [17] . Cross-sectional analysis from the Jackson Heart Study showed a difference in the association between adiponectin and LV mass between normotensive versus hypertensive participants [15] . However, earlier studies have not examined the association between adiponectin and cardiac structure several years after adiponectin was measured, as well as clearly described the difference in these associations after stratification by hypertension status. The aim of this study was to examine the association between serum adiponectin and multiple measures of LV structure and function 10 years after adiponectin was measured in the young biethnic cohort Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal's website (www.cardiovascularendocrinology.com).
available in The Coronary Artery Risk Development in Young Adults (CARDIA) study. On the basis of previous reports from the Jackson Heart Study, we stratified participants by hypertension status and assessed for the presence of linear as well as quadratic relationships [15] .
Methods

Study population
The CARDIA study began in [1985] [1986] . Overall, 5115 white and African-American men and women who were initially 18-30 years of age were recruited at clinical centers in Chicago, Illinois; Birmingham, Alabama; Oakland, California; and Minneapolis, Minnesota. Informed consent was obtained from each participant. The study was approved annually by the Institutional Review Boards of the participating centers. Echocardiograms were completed for the participants at year 25 (2010-2011) . The CARDIA study is ongoing. The current analysis includes CARDIA participants who had all of the following measurements ( Fig. 1 ): adiponectin measured at study year 15, all adjustment covariables measured at study year 15, a full set of echocardiographic variables at study year 25, and hypertensive status recorded at year 25.
Measurements
Details of CARDIA measurements have been reported previously [18] . Briefly, height and weight were measured in light clothing and without shoes at each visit. After resting 5 min, participants had blood pressure measured three times using a random zero sphygmomanometer and the last two values were averaged. Alcohol and tobacco use were assessed by self-report using a standardized questionnaire. Diabetes status was determined by fasting glucose of at least 126 mg/dl or by diabetic medication usage. Lipids were also assayed from blood samples.
After at least 8 h of fasting, blood samples were collected from seated participants. Samples were then centrifuged, aliquoted, and frozen at − 70°C within 90 min of collection. Radioimmunoassay (Linco Research Inc., St. Charles, Missouri,USA) was used to measure adiponectin using a polyclonal antibody raised in a rabbit and purified recombinant adiponectin with an effective range of 0.2-40 mg/l [19] . At adiponectin concentrations of 3 and 15 mg/l, intra-assay coefficients of variation were, respectively, 1.8 and 6.2% and interassay coefficients of variation were, respectively, 6.9 and 9.3% [20] .
The year 25 standardized echocardiographic protocol has been described extensively in the past and follows recommendations by the American Society of Echocardiography [18, 21] . Briefly, chamber sizes were determined by two-dimensional (2D) echocardiogram from apical four-chamber views and dimensions were determined by 2D guided M-mode echocardiogram from parasternal short axis views. Images were read at a central laboratory at Johns Hopkins University. Inter-reader, intrareader, and intraparticipant coefficients of variation for LV mass were less than 8% [18] . Echocardiographic variables analyzed were LV mass, LV mass index (LVMi), posterior wall thickness in diastole (PWT), ventricular septal thickness in diastole (VST), LV diastolic dimension (LVDD), and left ventricular ejection fraction. LV mass was calculated using the Devereux formula [22] . LVMi was defined as LV mass/height 1.7 because indexing to 1.7 rather than 2.7 has been shown to be a better marker of cardiovascular risk in obese populations, and thus more representative of the population that we studied [23] .
Statistical analysis
Participants were classified into quintiles of adiponectin concentration. Risk factor-adjusted echocardiographic variables were compared across quintiles of adiponectin concentration stratified by year 25 hypertension status. Hypertension was defined as blood pressure of at least 140/90 or use of an antihypertensive medication. Also, a sensitivity analysis was carried out with participants stratified by never versus ever hypertensive over the 25-year follow-up available in CARDIA.
Separate from the quintile analysis, adiponectin concentrations were skewed; thus, they were log 2 transformed to approximate a normal distribution. A 1 U increase in log 2 adiponectin represents a doubling of the adiponectin level. Adiponectin ranged from 1.0 to 64.0 mg/l within the sample studied; thus, a doubling of adiponectin concentration was well within the physiologic range and thus clinically relevant. Two regression models, one assuming linear and the second assuming quadratic or U-shaped relationships between year 15 log 2 adiponectin and year 25 echocardiographic variables, were assessed separately for normotensive and hypertensive participants. Both models were risk factor adjusted (age, race, sex, BMI, diabetes, LDL, HDL, alcohol and tobacco use), with model 1 containing only a linear term for log 2 adiponectin and model 2 containing both a linear and a quadratic term. A similar regression analysis was completed among participants stratified by never versus ever hypertensive over the 25-year follow-up available in CARDIA. Interaction of hypertension status with log 2 adiponectin was assessed by pooling the data for normotensive and hypertensive participants, introducing an indicator variable for hypertensive status into the model, and including in the model the products of the indicator variable with the linear and quadratic adiponectin terms. Separately, effect modification by ethnicity was examined by including interaction terms between log 2 adiponectin and ethnicity, as well as for log 2 adiponectin 2 and ethnicity.
A generalized additive model, implemented using the 'mgcv' package in R.3.3.3 (R foundation for statistical computing, Vienna, Austria), was used to model and show the nonlinear relation of LVMi with log 2 adiponectin by hypertension status group and adjusting for risk factors.
Results
The median adiponectin was 9.6 mg/l (interquartile range [6] [7] [8] [9] [10] [11] [12] [13] [14] . Table 1 shows the baseline demographic and clinical characteristics stratified by year 25 hypertensive status. The normotensive subcohort had a mean age of 40 4 years, a mean BMI of 27 6 kg/m 2 , a mean year 25 LVMi of 64 16, and 65% were white and 44% were men. The hypertensive subcohort had a mean age of 41 4 years, a mean BMI of 31 7 kg/m 2 , a mean LVMi of 77 23, and 35% were white and 43% were men. Relative to the normotensive cohort, the hypertensive cohort included participants who were heavier, had a worse lipid profile, and were more likely to smoke and to have diabetes. Similarly, the hypertensive cohort had increased year 25 LV mass and dimensions relative to the normotensive cohort. An interaction between the linear and quadratic adiponectin terms and hypertension status was present in the linear regression model pooling the normotensive and hypertensive data for LVMi (P = 0.02 for the linear term and P = 0.004 for the quadratic term). Table 2 shows the echocardiographic variables stratified by adiponectin quintile. Relative to the lowest quintile of adiponectin, normotensive participants from the highest adiponectin quintile had a lower risk factor-adjusted LV mass (− 7%), LVMi (− 6%), PWT (− 4%), and VST (− 7%) (all P ≤ 0.05). Similarly, among participants who were never hypertensive during the 25-year follow-up available in CARDIA (Supplemental Table 1 , Supplemental digital content 1, http://links.lww.com/ CAEN/A12), relative to the lowest quintile of adiponectin, participants from the highest quintile had a lower risk factor-adjusted LV mass (− 7%), LVMi (− 9%), PWT (− 4%), and VST (− 8%) (all P ≤ 0.005).
In contrast, relative to the lowest quintile of adiponectin, hypertensive participants from the highest quintile had a higher risk factor-adjusted LV mass (9%) and LVMi (8%) (both P ≤ 0.05). Also, mean LV mass for the highest adiponectin quintile was 45 g (30%) higher for hypertensive participants versus normotensive participants. Similarly, among participants who were hypertensive at any examination throughout the 25-year follow-up available in CARDIA (Supplemental Table 1 , Supplemental digital content 1, http://links.lww.com/ CAEN/A12), relative to the lowest quintile of adiponectin, participants from the highest quintile had a higher risk factor-adjusted LV mass (9%), LVMi (9%), and LVDD (3%) (all P ≤ 0.005). Table 3 shows the regression analysis for the echocardiographic variables stratified by hypertensive status. Similar to the quintile analysis, among normotensive participants, higher adiponectin was associated with lower LV mass, LVMi, PWT, and VST in the linear model. Figure 2 shows the linear relationship between LVMi and log 2 adiponectin among normotensive participants. In contrast, only the quadratic model for VST was significant for normotensive participants. As a result, there appears to be a linear inverse relationship between adiponectin and LV mass, LVMi, and PWT (all P ≤ 0.05) among normotensive participants. Supplemental Table 2 , Supplemental digital content 2, http://links.lww.com/ CAEN/A13 shows a similar linear inverse relationship among participants who were never hypertensive during the 25 years of CARDIA follow-up. Among normotensive participants, no significant interactions between adiponectin and ethnicity were present for any of the echocardiographic variables significant in the initial regression analysis other than VST. After stratification by race, the relationship between adiponectin and VST appeared to Adiponectin and cardiac structure Sharma et al. 59
be U-shaped in normotensive whites and inverse linear for normotensive blacks.
In contrast, among hypertensive participants, Table 3 shows that quadratic models better describe the association between adiponectin and echocardiographic parameters because four of the six echocardiographic parameters had significant quadratic terms. Also, the quintile analysis showed no significant difference in LVDD between the lowest and the highest adiponectin quintile, and as a result, this finding of a linear association for LVDD may be spurious. Figure 2 shows this U-shaped relationship between LVMi and log 2 adiponectin among hypertensive participants. As a result, there appears to be a U-shaped relationship between very low and very high adiponectin with higher LV mass, LVMi, PWT, and VST (all P ≤0.005) among hypertensive participants. Supplemental Table 2 , Supplemental digital content 2, http://links.lww.com/CAEN/A13 shows a similar U-shaped relationship among participants who were hypertensive at any point during the 25 years of CARDIA follow-up. Among hypertensive participants, no significant interactions were present between adiponectin and ethnicity for any of the echocardiographic variables. To further explore the causes for this U-shaped relationship, Supplemental Table 3 , Supplemental digital content 3, http://links.lww.com/CAEN/A14 shows the demographic and clinical characteristics of the hypertensive cohort stratified by adiponectin quintile. None of these variables, other than increased use of tobacco and alcohol among participants with higher adiponectin, appears to explain the association between higher adiponectin and higher LVMi among hypertensive participants. Supplemental Table 4 , Supplemental digital content 4, http://links.lww. com/CAEN/A15 shows the full quadratic models, including linear terms, for both normotensive and hypertensive participants. 
Discussion Principal findings
Among normotensive participants, higher adiponectin was associated linearly with lower risk factor-adjusted LV mass, LVMi, PWT, and VST 10 years later. In contrast, among hypertensive participants, there was a U-shaped relationship between adiponectin and risk factor-adjusted LV mass, LVMi, PWT, and VST 10 years later.
Earlier studies did not report these differences between normotensive and hypertensive individuals, perhaps because most earlier studies did not stratify participants by hypertension status. Also, earlier studies examined only the cross-sectional association between adiponectin and cardiac structure and function, whereas we assessed the longitudinal association between adiponectin and LV structure 10 years later.
Results relative to earlier studies
An earlier study using ECG as the means of detecting LV hypertrophy showed that higher adiponectin was associated with less left ventricular hypertrophy in both normotensive and hypertensive participants [17] . However, our study used echocardiogram, which is a more sensitive measure of left ventricular hypertrophy than ECG [24] .
An analysis from the Jackson Heart study showed that among normotensive participants, higher adiponectin was associated with lower LVMi, but there was no significant association between adiponectin and LVMi among hypertensive participants as a whole [15] . CARDIA includes both blacks and whites, whereas the Jackson Heart Study only includes blacks. Earlier analysis from the Dallas Heart Study showed that blacks have higher LV mass than whites even after adjustment for age, sex, and systolic blood pressure [25] . As a result, ethnic differences in the populations studied may explain the discrepancy with the current study. Nevertheless, we showed the lack of an interaction between adiponectin and ethnicity for LVMi.
Potential mechanisms
Several mechanisms may contribute toward how higher adiponectin is associated with lower LVMi and wall thickness among normotensive participants. An earlier study in mice showed that adiponectin decreased pressure overload-induced left ventricular hypertrophy [8] .
Adiponectin deficiency also leads to decreased activation of AMPK pathways, and thus less vascular endothelial growth factor-mediated angiogenesis; this may lead to increased compensatory concentric remodeling and fibrosis [8] . Adiponectin also inhibits reactive oxygeninduced cardiomyocyte hypertrophy and protects against angiotensin II-induced fibrosis [3, 4] . Earlier studies also showed that low adiponectin levels are associated with endothelial and microvascular dysfunction, which may also contribute toward the association between low adiponectin and higher LV mass observed in normotensive participants [26] . Also, adiponectin is associated inversely with BMI [1] . As a result, individuals in the higher adiponectin quintiles have lower BMI, which is also associated with lower LVMi [22] .
The mechanism for the U-shaped association between adiponectin with LVMi and wall thickness among hypertensive participants likely differs from that in normotensive participants. Figure 2 shows that the lowest point of the U-shaped association observed in hypertensives occurs at log 2 (adiponectin)≈2.5 or where adiponectin≈5.6 ng/ml. Because the median adiponectin is 9.6 ng/ml (interquartile range 6-14) in our sample, most hypertensive participants fall in the range of the association between higher adiponectin and higher LVMi. Higher tobacco use among hypertensive participants with higher adiponectin may partially explain the association between higher adiponectin and LVMi; we attempted to account for this by adjusting for tobacco use, but some residual confounding may exist [18] . An earlier study from CARDIA showed that although higher adiponectin was associated with increased coronary artery calcium, it was also associated with higher HDL and lower triglycerides and C-reactive protein, suggesting that the higher adiponectin may be a compensatory response to underlying macrovascular disease [13] . Also, earlier animal studies showed that rats fed high-salt diets developed hypertension and higher adiponectin levels. The elevated adiponectin levels persisted even after the treatment of the hypertension with direct vasodilators and sympathetic blockade using hydralazine and clonidine. These elevated adiponectin levels only resolved when the renin-angiotensin system was blocked by telmisartan or eplerenone, suggesting that the reninangiotensin system mediates elevated adiponectin levels observed in hypertensive individuals because of higher salt intake, rather than the increased blood pressure itself [27] . This may explain our findings in hypertensive participants because these individuals often have increased salt intake relative to a normotensive population. The increased salt intake increases blood pressure and thus LVMi, but the salt intake also increases adiponectin levels in a compensatory response to the adverse effects of the increased salt.
Study limitations and future research
One of the limitations of the current study was that we did not have repeated measures of adiponectin measured contemporaneously with repeated measures of echocardiographic variables and could not assess how change in adiponectin related to change in echocardiographic parameters. Also, we stratified participants by hypertension status at year 25 and did not account for the duration of hypertension. However, the sensitivity analysis that stratified by ever-hypertensive versus neverhypertensive yielded similar results. Another limitation of this study was that this was an observational study and, as a result, we could only observe associations, rather than causation. Another limitation is that we could not adjust for the fact that several medications can affect adiponectin concentrations. For example, pravastatin increases serum adiponectin concentrations, whereas atorvastatin decreases serum adiponectin concentrations [28, 29] . Because adiponectin concentrations respond differently to medications even within the same class, we could not account for all the different medications that patients were currently on.
The current study showed that normotensive participants in the highest adiponectin quintile had a 6% lower risk factor adjusted LVMi relative to the lowest adiponectin quintile. Also, there was a 45 g (30%) difference in risk factor-adjusted LV mass between hypertensive versus normotensive participants in the highest adiponectin quintile. Earlier studies showed that higher LV mass is associated with worse clinical outcomes [30] . Future study, likely initially in animal models, is required to assess whether adiponectin supplementation causes reverse remodeling and improvements in clinical endpoints such as mortality and the development of heart failure. If these beneficial effects of adiponectin supplementation are found in animal models, adiponectin receptor agonists may represent a potential therapeutic target for future drug development. However, we also showed that hypertensive participants in the highest adiponectin quintile had an 8% higher risk factor adjusted LVMi relative to the lowest adiponectin quintile. As a result, further study is required to determine whether higher adiponectin causes the higher LVMi in hypertensive individuals or whether the association between higher adiponectin and higher LVMi is merely a compensatory response to hypertension-induced increase in LVMi. If higher adiponectin is merely a compensatory response to hypertension-induced LV hypertrophy in hypertensive individuals, adiponectin supplementation may be a potential therapeutic target for drug therapy as noted earlier. However, if higher adiponectin is a direct cause of pathologic LV hypertrophy in hypertensive individuals, the use of adiponectin receptor agonists for therapeutic purposes becomes less clear.
Conclusion
We observed the novel finding of a linear inverse relationship between adiponectin with LVMi and wall thickness 10 years later among normotensive participants. In contrast, there was a U-shaped relationship between adiponectin with LVMi and wall thickness 10 years later among hypertensive participants. Among normotensive participants, adiponectin may be a useful marker of less adverse future cardiac structure. Further study is required to determine whether adiponectin receptor agonists may provide a benefit among these individuals by inducing reverse remodeling or decreasing mortality and the development of heart failure. Among hypertensive participants, further study is required to assess the prognostic and therapeutic use of adiponectin because the underlying relationship between adiponectin and LV structure remains less clear.
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